Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.59 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.59 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380980 | 1.00 | CFTR (1.00) | CFTRSIRT1MAPTMEN1KMT2A | |
| SCHEMBL12648530 | 1.00 | CFTR (1.00) | CFTRSIRT1MAPTMEN1KMT2A | |
| SCHEMBL12648543 | 0.97 | CFTR (0.94) | CFTRSIRT1MAPTMEN1KMT2A | |
| SCHEMBL17133546 | 0.92 | CFTR (0.86) | CFTRSIRT1MAPTMEN1KMT2A | |
| SCHEMBL14082216 | 0.91 | CFTR (0.83) | CFTRSIRT1MAPTMEN1KMT2A | |
| SCHEMBL12648525 | 0.88 | CFTR (0.78) | CFTRSIRT1MAPTMEN1KMT2A | |
| SCHEMBL14082244 | 0.88 | CFTR (0.78) | CFTRSIRT1MAPTMEN1KMT2A | |
| SCHEMBL12671992 | 0.87 | CFTR (0.76) | CFTRSIRT1MAPTMEN1KMT2A | |
| SCHEMBL12648528 | 0.87 | CFTR (0.77) | CFTRMAPTMEN1KMT2AKDM4E | |
| SCHEMBL12648542 | 0.84 | CFTR (0.72) | CFTRSIRT1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049950-A1 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | ARCTURUS THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4426266-A1 | LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Arcturus Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12070509-B2 | Nucleic acids and methods of treatment for cystic fibrosis | ARCTURUS THERAPEUTICS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230174600-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH | 2023-06-08 | — | — | US | disclosed |
| US-20230159449-A1 | LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | ARCTURUS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023081776-A1 | LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-116096430-A | Compositions and methods for treating cystic fibrosis | 衣阿华大学研究基金会 | 2023-05-09 | — | — | CN | disclosed |
| EP-4143217-A2 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Arcturus Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143326-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | University of Iowa Research Foundation (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-114641318-A | Compositions and methods for treating cystic fibrosis | 衣阿华大学研究基金会 | 2022-06-17 | — | — | CN | disclosed |
| CN-114340683-A | Methods and compositions for transgene expression | 衣阿华大学研究基金会 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049950-A1 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, RNMT, RNGTT | CFTR 1/4885SIRT1 4286/4885MAPT 4877/4885 |
| US-20230159449-A1 | LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, RNMT, LIPA | CFTR 1/4885SIRT1 3909/4885MAPT 4814/4885 |
| US-12070509-B2 | Nucleic acids and methods of treatment for cystic fibrosis | CFTR, RNMT, RNGTT | CFTR 1/4885SIRT1 4286/4885MAPT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.